Rhythm Pharmaceuticals (NASDAQ:RYTM) Given “Buy” Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Rhythm Pharmaceuticals (NASDAQ:RYTM) in a report released on Monday morning,Benzinga reports. HC Wainwright currently has a $70.00 price objective on the stock. HC Wainwright also issued estimates for Rhythm Pharmaceuticals’ Q1 2025 earnings at ($0.74) EPS, Q2 2025 earnings at ($0.72) EPS, FY2025 earnings at ($2.87) EPS, Q1 2026 earnings at ($0.60) EPS, Q2 2026 earnings at ($0.40) EPS, Q3 2026 earnings at ($0.31) EPS and Q4 2026 earnings at ($0.18) EPS.

Several other research analysts have also commented on the stock. Jefferies Financial Group assumed coverage on shares of Rhythm Pharmaceuticals in a research note on Thursday, January 2nd. They set a “buy” rating and a $80.00 price objective for the company. Morgan Stanley reiterated an “overweight” rating and set a $72.00 price target on shares of Rhythm Pharmaceuticals in a report on Friday, March 7th. Needham & Company LLC boosted their target price on Rhythm Pharmaceuticals from $64.00 to $66.00 and gave the company a “buy” rating in a research report on Tuesday, March 18th. Stifel Nicolaus started coverage on Rhythm Pharmaceuticals in a research report on Wednesday, March 5th. They issued a “buy” rating and a $78.00 price objective on the stock. Finally, Oppenheimer started coverage on shares of Rhythm Pharmaceuticals in a research note on Friday, December 20th. They set an “outperform” rating and a $76.00 target price for the company. One research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $69.46.

Rhythm Pharmaceuticals Trading Up 2.6 %

Shares of NASDAQ:RYTM opened at $54.30 on Monday. The company has a market cap of $3.43 billion, a price-to-earnings ratio of -12.54 and a beta of 2.30. Rhythm Pharmaceuticals has a 12 month low of $35.17 and a 12 month high of $68.58. The company has a 50-day moving average price of $55.26 and a 200 day moving average price of $55.02.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.03). The company had revenue of $41.83 million during the quarter, compared to the consensus estimate of $38.48 million. Rhythm Pharmaceuticals had a negative net margin of 230.07% and a negative return on equity of 367.36%. As a group, equities analysts forecast that Rhythm Pharmaceuticals will post -4.32 EPS for the current year.

Insider Activity at Rhythm Pharmaceuticals

In other Rhythm Pharmaceuticals news, CAO Christopher Paul German sold 635 shares of Rhythm Pharmaceuticals stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $57.22, for a total value of $36,334.70. Following the transaction, the chief accounting officer now owns 2,070 shares in the company, valued at $118,445.40. The trade was a 23.48 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Joseph Shulman sold 1,281 shares of the stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $59.43, for a total transaction of $76,129.83. Following the sale, the insider now directly owns 2,657 shares of the company’s stock, valued at approximately $157,905.51. The trade was a 32.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 108,131 shares of company stock valued at $5,781,098 over the last ninety days. 5.60% of the stock is owned by company insiders.

Institutional Trading of Rhythm Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the business. SRS Capital Advisors Inc. increased its position in Rhythm Pharmaceuticals by 740.7% during the 4th quarter. SRS Capital Advisors Inc. now owns 454 shares of the company’s stock valued at $25,000 after buying an additional 400 shares in the last quarter. Raleigh Capital Management Inc. acquired a new position in shares of Rhythm Pharmaceuticals during the fourth quarter valued at about $28,000. SBI Securities Co. Ltd. acquired a new position in shares of Rhythm Pharmaceuticals during the fourth quarter valued at about $37,000. R Squared Ltd acquired a new stake in Rhythm Pharmaceuticals in the 4th quarter worth approximately $44,000. Finally, State of Wyoming purchased a new stake in Rhythm Pharmaceuticals during the 4th quarter worth approximately $61,000.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.